Cell Therapy Drug Product Development: Technical Considerations and Challenges

被引:4
|
作者
Weng, Lindong [1 ]
机构
[1] Novo Nordisk Res Ctr Seattle Inc, Seattle, WA 98109 USA
关键词
Cryopreservation; Controlled-rate freezer; Cryoprotectant; Formulation; Fill and finish; Stability; Dose preparation; CAR T; CRYOPRESERVATION;
D O I
10.1016/j.xphs.2023.08.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cell therapy uses living cells as a drug to treat diseases. To develop a cell therapy drug product (DP), cryopreservation plays a central role in extending the shelf life of these living medicines by pausing their biological activities, especially preventing degradation, at a temperature as low as liquid nitrogen. This helps overcome the temporal and geographical gaps between centralized manufacturing and clinical administration, as well as allowing sufficient time for full release testing and flexibility in scheduling patients for administration. Cryopreservation determines or influences several key manufacturing, logistical, or clinical in-use processes, including formulation, filling, controlled rate freezing, cryogenic storage and transportation, thawing, and dose preparation. This article overviews the key technical aspects of cell therapy DP development and elucidates fundamental principles of cryobiology that should be considered when we design and optimize the relevant processes. This article also discusses the challenges that motivate continued innovation for cell therapy drug product development.(c) 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2615 / 2620
页数:6
相关论文
共 50 条
  • [41] Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research
    Patricia Gálvez Martín
    Adolfina Ruiz Martinez
    Visitación Gallardo Lara
    Beatriz Clares Naveros
    Clinical and Experimental Medicine, 2014, 14 : 25 - 33
  • [42] Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research
    Galvez Martin, Patricia
    Ruiz Martinez, Adolfina
    Gallardo Lara, Visitacin
    Clares Naveros, Beatriz
    CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 14 (01) : 25 - 33
  • [43] Prospect of drug product quality - Regulatory considerations
    Uchiyama, M
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 1996, : 63 - 64
  • [44] Selecting a Cell Engineering Methodology During Cell Therapy Product Development
    Timmins, Lauren M.
    Burr, Alexandra M.
    Carroll, Kristina
    Keefe, Robert
    Teryek, Matthew
    Cantolupo, Louis J.
    van der Loo, Johannes C. M.
    Heathman, Thomas R. J.
    Gormley, Adam
    Smith, David
    Parekkadan, Biju
    CELL TRANSPLANTATION, 2021, 30
  • [45] Prospects for drug product quality - regulatory considerations
    Pharmaceutical Technology, 1996, 20 (10):
  • [46] Technical challenges for FLASH proton therapy
    Jolly, Simon
    Owen, Hywel
    Schippers, Marco
    Welsch, Carsten
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2020, 78 : 71 - 82
  • [47] Practical Product Development Challenges
    Ashruf C.
    IEEE Engineering Management Review, 2023, 51 (02): : 152 - 165
  • [48] CONSIDERATIONS FOR THE DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CELL AND GENE THERAPY PRODUCTS
    Sharpe, M.
    CYTOTHERAPY, 2017, 19 (05) : S44 - S44
  • [49] Technical considerations for renal replacement therapy in children
    Bunchman, Timothy E.
    Brophy, Patrick D.
    Goldstein, Stuart L.
    SEMINARS IN NEPHROLOGY, 2008, 28 (05) : 488 - 492
  • [50] TECHNICAL CONSIDERATIONS IN SURGICAL THERAPY FOR COARCTATION OF THE AORTA
    GROSS, RE
    SURGERY, 1946, 20 (01) : 1 - 8